NCT04818632 (AZD9833) is a Phase 1 clinical trial of AZD9833 in ER+, HER2-, Metastatic Breast Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT04818632?

NCT04818632 is sponsored by AstraZeneca.

What drugs are being tested in NCT04818632?

Interventions in NCT04818632: AZD9833, AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus.

What condition does NCT04818632 study?

NCT04818632 studies ER+, HER2-, Metastatic Breast Cancer.

Is NCT04818632 still recruiting?

NCT04818632 is currently completed. Last updated 17 December 2024.

Last reviewed 2024-12-17 · How we verify

NCT04818632: AZD9833

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD9833 China PK Study

Completed Phase 1 Last updated 17 December 2024

What this trial tests

Phase 1 trial testing AZD9833 in ER+, HER2-, Metastatic Breast Cancer in 28 participants. Completed in 7 September 2023.

Timeline

12 November 2021

Primary endpoint
7 September 2023

7 September 2023

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	12 November 2021
Primary completion	7 September 2023
Estimated completion	7 September 2023
Sites	4 locations across China

Drugs / interventions tested

AZD9833 — full drug profile →
AZD9833 — full drug profile →
AZD9833 with palbociclib — full drug profile →
AZD9833 with everolimus — full drug profile →

Conditions studied

ER+, HER2-, Metastatic Breast Cancer — all drugs for ER+, HER2-, Metastatic Breast Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, female only, with ER+, HER2-, Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).
Ali S, Zhou J. · · 2023 · cited 56× · PMID 37207534 · DOI 10.1016/j.ejmech.2023.115476
Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
Yao J, Tao Y, Hu Z, Li J, et al · · 2023 · cited 5× · PMID 37808197 · DOI 10.3389/fphar.2023.1225951

Verify or expand the search:

Other trials of AZD9833

Trials testing the same drug.

NCT05438303 — Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celec · Phase 1 · completed
NCT04964934 — Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) · Phase 3 · active not recruiting
NCT04711252 — A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Ne · Phase 3 · active not recruiting
NCT04588298 — A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer · Phase 2 · completed
NCT04541433 — A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer · Phase 1 · completed

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04818632 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 17 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04818632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing